CRS 2023 Annual Meeting & Expo

who enables release over time? we do.

date: July 24-28, 2023
location: Paris Hotel, Las Vegas, NV
booth: Ashland Booth #206

Ashland solvers’ expertise in controlled release polymers results in tailored release profiles that meet your requirements for active pharmaceutical ingredient delivery.

key products

sneak peek at new Viatel™ ultrapure bioresorbable polymers – stay tuned
viatel™ bioresorbable polymers control release over time. These polymers are the building blocks for developing long-acting injectable depots, an established technology to improve therapeutic efficacy and patient compliance. All Viatel™ bioresorbable polymers can be custom produced.
benecel™ xrf hpmc are fine particle grades designed for optimal performance in large-scale, high speed tableting. This product provides better powder flowability, produces robust tablets under high-throughput continuous manufacturing conditions and for challenging multi-layer SR tablets, and with lower nitrosamine levels, improves formulation stability by minimizing the potential for interaction between API and excipients that results in NDMA.
klucel™ xtend hpc has been shown to match the release profile of widely used hypromellose controlled release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with Klucel™ xtend HPC offers the possibility of smaller pills or higher dosage. Designed to deliver unsurpassed process versatility and release profile efficiency, even with hot-melt extrusion.
aqualon™ ethylcellulose (EC) and Ashland® EC pharm ultra are non-ionic ethyl ethers of cellulose, soluble in a wide range of organic solvents. Aqualon™ EC is produced using an aqueous slurry-based process while Ashland® EC is produced using an organic solvent based process. Typically, ethylcellulose is used as a non-swellable, insoluble component in matrix or coating systems. When water-soluble

Visit our booth to learn more about our key products and other controlled release polymers to meet your needs.

Visit with us at CRS to learn about the ways we are always solving:

Long-Acting Injectables (LAI): Improved Bioresorbable Polymers for Formulation Success

date: Tuesday, July 25, 2023
time: 8:00 am to 9:00 am
room: Champagne 3 & 4

abstract:
This presentation will provide an overview on bioresorbable polymers geared towards long-acting injectable (LAI) formulations. It will begin by introducing the features and benefits of lactide, glycolide, caprolactone, and PEGylated polymer chemistries that are currently utilized for complex drug delivery. After the foundation is set, Ashland will discuss many of the challenges in this field and how polymer technologies and processing know-how can be used to solve them. In addition, Ashland is excited to introduce our improved Viatel™ Ultrapure polymer grades, which are designed to offer enhanced polymer purity for sensitive drug molecules and their respective formulations.

Brad Minrovic, PhD
Technical Account Manager, Pharmaceuticals
Ashland Specialty Ingredients
Wilmington, Delaware, United States

Title: Effects of monomer on PLGA based long-acting injectables’ release and stability

poster number: 256

authors: Cory Mahnen, Kamaru Lawal, Fengyuan Yang, Patrick Duffy, Thomas Dürig

introduction: Long acting injectables (LAI’s) frequently utilize bio-resorbable polymers to control the release of active pharmaceutical ingredients via tunable degradation rates. One commonly used bioresorbable polymer is poly (lactic-co-glycolic acid), or PLGA because they allow for tuning of co-monomer ratio, molecular weight, and end group to meet a characteristic degradation rate1. Degradation rates, geometry and, API characteristics such as hydrophobicity and loading determine the pharmacokinetic profile of the long-acting injectable product2. One less studied aspect of PLGA bio-resorbable polymers is the effect monomers can have on the degradation rate and drug stability. The purpose of this study is to examine the effects monomer has on long-acting injectable formulations release and stability.

Title: Hydrodynamic robustness of Klucel™ xtend hydroxypropylcellulose (HPC) for modified release matrix systems

poster number: 709

authors: Quyen Schwing, Kapish Karan, Thomas Dürig
Ashland Specialty Ingredients, Wilmington, DE 19808

Introduction: Extended-release formulations provide several benefits, such as reduced dosing frequency, improved efficacy, reduced adverse effects, and improved patient compliance. Among the various types of extended-release dosage forms, the hydrophilic matrix is the most widely used platform for drug delivery. Hydroxypropyl methylcellulose (HPMC) is the most common polymer for controlled-release oral dosage forms. To overcome the limitations of commercially available HPMC grades, a Klucel™ xtend hydroxypropylcellulose (HPC) grade has been evaluated for its hydrodynamic robustness in controlled release matrix systems.

Title: Development of PLGA-Based Implants Using Hot Melt Extrusion for Sustained Release of Drugs: The Impacts of PLGA’s Material Characteristics

poster number: 676

authors: Fengyuan Yang; Ryan Stahnke; Kamaru Lawal; Cory Mahnen; Keyvan Mollaeian; Shuyu Xu; Patrick Duffy; Thomas Dürig

Introduction: Poly (lactic-co-glycolic acid), or PLGA, is one of the most extensively used copolymers for controlled drug delivery applications. There are many drug products (dosage forms) containing PLGA that are approved by the FDA and EMA for human use. Hot melt extrusion (HME) processed implant is one of the commercialized PLGA-based drug delivery products, which has solid, well-designed shape and rigid structures. These implants afford efficient locoregional drug delivery on the spot of interest for months or even years. In general, there are a variety of material, processing, and physiological factors that impact the degradation rates of PLGA-based implants and concurrent drug release kinetics. The objective of this study is to investigate the impacts of PLGA’s material characteristics on PLGA degradation and subsequent drug release behavior from the implants.